The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Abstract
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate. We performed a placebo-controlled, double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs. The hypothesis was that octreotide LAR prolongs time to tumor progression and survival. Patients and Methods: Treatment-naive patients were randomly assigned to either placebo or octreotide LAR 30 mg intramuscularly in monthly intervals until tumor progression or death. The primary efficacy end point was time to tumor progression. Secondary end points were survival time and tumor response. This report is based on 67 tumor progressions and 16 observed deaths in 85 patients at the time of the planned interim analysis. Results: Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR] = 0.34; 95% CI, 0.20 to 0.59; P = .000072). After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group. Functionally active and inactive tumors responded similarly. The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor. Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively. The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18). Conclusion: Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs. Because of the low number of observed deaths, survival analysis was not confirmatory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Sarmiento, J. M., Heywood, G., Rubin, J., Ilstrup, D. M., Nagorney, D. M., & Que, F. G. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00230-8 · Cited by 773
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
Kulke, M. H., Lenz, H.-J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., Bergsland, E., Stuart, K., Tye, L., Huang, X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9020 · Cited by 623
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Öberg, K., Kvols, L., Caplin, M., Delle Fave, G., de Herder, W., Rindi, G., Ruszniewski, P., Woltering, E. A., & Wiedenmann, B. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh216 · Cited by 577
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Kulke, M. H., Stuart, K., Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Vincitore, M., Michelini, A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6046 · Cited by 513
Faiss, S., Pape, U.-F., Böhmig, M., Dörffel, Y., Mansmann, U., Golder, W., Riecken, E. O., & Wiedenmann, B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.142 · Cited by 501
Self-citationTumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr, C., Pless, M., Maëcke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A. R., & Mueller‐Brand, J. (2002) · PubMed · Cited by 445
Gupta, S., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., et al. (2005) · Cancer · doi:10.1002/cncr.21389 · Cited by 433
Müller, H.-H., & Schäfer, H. (2001) · Biometrics · doi:10.1111/j.0006-341x.2001.00886.x · Cited by 372
Self-citationSchoenfeld, D. A., & Richter, J. R. (1982) · Biometrics · doi:10.2307/2530299 · Cited by 354
Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jürgensen, R., Stein, K., Schäfer, H., Bruns, C., et al. (1996) · Gut · doi:10.1136/gut.38.3.430 · Cited by 342
Self-citationValkema, R., Pauwels, S., Kvols, L. K., Barone, R., Jamar, F., Bakker, W. H., Kwekkeboom, D. J., Bouterfa, H., & Krenning, E. P. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.01.001 · Cited by 313
Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver Metastases
Hellman, P., Lundström, T., Öhrvall, U., Eriksson, B., Skogseid, B., Öberg, K., Tiensuu Janson, E., & Åkerström, G. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6630-z · Cited by 300
Di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., Di Leo, A., & ITMO Association (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<402::aid-cncr25>3.0.co;2-4 · Cited by 296
Saltz, L., Trochanowski, B., Buckley, M., Heffernan, B., Niedzwiecki, D., Tao, Y., & Kelsen, D. (1993) · Cancer · doi:10.1002/1097-0142(19930701)72:1<244::aid-cncr2820720143>3.0.co;2-q · Cited by 260
Aggressive surgery for metastatic liver neuroendocrine tumors
Norton, J. A., Warren, R. S., Kelly, M. G., Zuraek, M. B., & Jensen, R. T. (2003) · Surgery · doi:10.1016/j.surg.2003.07.025 · Cited by 255
Arnold, R., Rinke, A., Klose, K.-J., Müller, H.-H., Wied, M., Zamzow, K., Schmidt, C., Schade-Brittinger, C., Barth, P., Moll, R., et al. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00481-7 · Cited by 254
Self-citationAntitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
Aparicio, T., Ducreux, M., Baudin, E., Sabourin, J.-C., De Baere, T., Mitry, E., Schlumberger, M., & Rougier, P. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00073-9 · Cited by 226
Theodoropoulou, M., Zhang, J., Laupheimer, S., Paez-Pereda, M., Erneux, C., Florio, T., Pagotto, U., & Stalla, G. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1189 · Cited by 216
Shojamanesh, H., Gibril, F., Louie, A., Ojeaburu, J. V., Bashir, S., Abou‐Saif, A., & Jensen, R. T. (2002) · Cancer · doi:10.1002/cncr.10195 · Cited by 215
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Ducreux, M. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02003-7 · Cited by 196
Arnold, R., Wilke, A., Rinke, A., Mayer, C., Kann, P. H., Klose, K., Scherag, A., Hahmann, M., Müller, H., & Barth, P. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.052 · Cited by 192
Self-citationMethod for Dissection of Mesenteric Metastases in Mid‐gut Carcinoid Tumors
Öhrvall, U., Eriksson, B. K., Juhlin, C., Karacagil, S., Rastad, J., Hellman, P., & Åkerström, G. (2000) · World Journal of Surgery · doi:10.1007/s002680010232 · Cited by 163
Kress, O., Wagner, H., Wied, M., Klose, K.-J., Arnold, R., & Alfke, H. (2003) · Digestion · doi:10.1159/000074522 · Cited by 150
Self-citationFlorio, T. (2007) · Frontiers in bioscience · doi:10.2741/2722 · Cited by 128
Eriksson, J., Stalberg, P. L. H., Nilsson, A., Krause, J., Lundberg, C. E., Skogseid, B. M., Granberg, D. O., Eriksson, B. K., Åkerström, G., & Hellman, P. (2008) · World Journal of Surgery · doi:10.1007/s00268-008-9510-3 · Cited by 113
Complete histological regression of metastatic carcinoid tumour after treatment with octreotide
Imtiaz, K. E., Monteith, P., & Khaleeli, A. A. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01126.x · Cited by 39
Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide
Joensuu, H., Kätkä, K., & Kujari, H. P. (1992) · European Journal of Endocrinology · doi:10.1530/acta.0.1260184 · Cited by 37
Cited by
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Metadata
- Authors
- Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., Harder, J., Arnold, C., Gress, T., & Arnold, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-10-01
- Volume
- 27
- Issue
- 28
- Pages
- 4656-4663
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2137142564
- Cited by
- 2,508
- References
- 31
- FWCI
- 89.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.